Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia.
Phase I Study of Escalating Single and Multiple Doses of Mana 312 Multi Tumor-Associated Antigen T cells Administered to Adult Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplant
Study Type: Treatment
Phase: I
NCTID: NCT04679194
Principal Investigator:
Haitham Abdelhakim
Phase I/II Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells VCAR33 in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Study Type: Treatment
Phase: I/II
NCTID: NCT05984199
Principal Investigator:
Muhammad Umair Mushtaq
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination with Standard Chemotherapy for the Treatment of Newly-Diagnosed Acute Myeloid Leukemia
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
Study Type: Treatment
Phase: I
NCTID: NCT06146257
Principal Investigator:
Jesus Gonzalez Lugo
A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician?s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia.
Study Type: Treatment
Phase: III
NCTID: NCT04778397
Principal Investigator:
Jesus Gonzalez Lugo
A Phase IIA, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 a Liposomal Grb2 Antisense Oligonucleotide in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia AML Who Are Ineligible for Intensive Induction Therapy
A Phase Ib/II Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia AML
Study Type: Treatment
Phase: I/II
NCTID: NCT06634394
Principal Investigator:
Tara Lin